Retatrutide, a Superpowerful Obesity Drug, Is Not Yet FDA-Approved — but Knockoffs Abound

Retatrutide, a Superpowerful Obesity Drug, Is Not Yet FDA-Approved — but Knockoffs Abound

GLP-1 drugs such as semaglutide (Wegovy, Ozempic), tirzepatide (Zepbound, Mounjaro), and orforglipron (Foundayo) have become wildly popular because they can help people lose a substantial amount of weight. Soon there could be a new option, retatrutide (nicknamed “reta” and “Godzilla”), that promises unprecedented weight loss — but it’s not ready for prime time quite yet. Unlike the other GLP-1 medications, retatrutide hasn’t been approved by the…

The Obesity Drug Race Moves Past Ozempic with a Shot Targeting Three Hormones

Eli Lilly's retatrutide produced up to 30.3% average weight loss in phase 3 trials. Approval is not expected before 2027 at the earliest.

Eli Lilly (NYSE: LLY) Files For Next-Gen Weight-Loss Drug Retatrutide In Q1 2027, Leaving Novo Nordisk (NYSE: NVO) Scrambling

Eli Lilly (NYSE: LLY) has officially confirmed it will submit a Biologics License Application to the U.S. Food and Drug Administration for retatrutide in the first quarter of 2027. The announcement marks a major milestone for the drugmaker, which already leads the weight-loss market through its blockbuster medication Zepbound. The filing timeline puts Eli Lilly in an increasingly dominant position over its closest rival, Novo Nordisk (NYSE: NVO)…

Eli Lilly's Timing of the FDA Filing of Its Next Weight-Loss Drug Is Now Official -- and Novo Nordisk Has a Problem

Can anyone take the top spot away from Eli Lilly in the anti-obesity area?